# A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

> **NCT02085473** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 60 (actual)

## Conditions studied

- Asthma
- Healthy Subjects or Volunteers

## Interventions

- **BIOLOGICAL:** Tralokinumab 300 mg

## Key facts

- **NCT ID:** NCT02085473
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-19
- **Primary completion:** 2014-07-10
- **Final completion:** 2014-07-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02085473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02085473, "A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02085473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*